Low — 0 expert voices, 0 KB claims; quant/fundamentals only
Position sizing
If owned, a small income/defensive sleeve (~1–2%) — not a conviction position; wait for a better entry
Next catalyst
2026-07-29 Q2'26 earnings (Street EPS $5.16)
Single biggest risk
Catastrophe/reserve normalization — today's low combined ratio and reserve releases are not repeatable
One-line thesis. Allstate screens statistically cheap (5.5× trailing EPS, 0.19 beta) because it is a well-run cyclical insurer printing near-record underwriting profit off a benign-catastrophe, reserve-release quarter — but the Street's own estimates have EPS falling ~$30 → ~$25 through 2028 as that normalizes, the stock sits at its 52-week high on an 84 RSI, and consensus is a $250 Hold. Good company, wrong moment: Watch.
◆ Synthos call — HoldALL is a solid business largely reflected at ~$245 — fine to keep, no reason to chase; it gets interesting again below ~$208.
Downside Risk (lower = safer)
5/10 · Moderate
Cheap headline P/E and 0.19 beta, but earnings sit at a benign-cat cyclical peak and RSI 84 at the 52-wk high.
Growth Quality
4/10 · Moderate
FY26E-28E EPS estimates DECLINE (~$30→$25) as cat losses and reserve releases normalize; mid-single-digit premium growth.
Exponential Potential
2/10 · Low
Mature US P&C insurer, no acceleration, TAM saturated — a compounder-at-best, not an exponential.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 1%/yrTo justify today’s $250, earnings would have to compound roughly 1% a year for 10 years (9% discount rate). Analysts forecast ~10%/yr, so the market is pricing in LESS than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Allstate is one of America's biggest car- and home-insurance companies ("You're in good hands"). It collects premiums, pays out claims, and pockets the difference plus the investment income on the money it holds. Right now that spread is unusually fat: 2025's California-wildfire losses have faded, storm losses have been mild, and the company even got money back by lowering old claim reserves — so recent profit is at a high-water mark.
That's why the stock looks so cheap on paper (about 5–6× last year's earnings). The problem: insurance profit is lumpy. The pros who follow it expect earnings to come back down over the next couple of years as a normal amount of hurricanes and wildfires returns. Meanwhile the stock just hit a fresh 52-week high and is technically "overbought." Wall Street's average price target is essentially where it trades today.
Our verdict is Watch — a fine, defensive, dividend-paying business, but you're buying it at a good-times peak with little margin of safety. Better to wait for a pullback or a proof that the earnings power is durable.
Here's what our three scores mean in everyday terms:
Downside Risk 5/10 (middle). The balance sheet is solid and the stock barely moves with the market (very low beta) — but the earnings you're paying for are at a cyclical peak, and it's technically stretched.
Growth Quality 4/10 (below average). It grows slowly, and analysts actually expect profits to shrink over the next two years as luck normalizes.
Exponential Potential 2/10 (low). This is a mature, saturated business. Don't expect it to multiply.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = ALL · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$250.33
Market cap$64B
P/E trailing11×
P/E FY26E / FY27E8× / 10×
EV / Sales1.1×
EV / EBITDA4.4×
Gross margin39.8%
Net margin18.1%
Dividend yield1.66%
Beta0.192
52-wk range$190 – $250
RSI(14)84
50 / 200-DMA$220 / $209
12-mo return+25% (SPY +21%)
Street target$250 ($225–$281)
Analyst grades20 Buy · 22 Hold · 1 Sell
FMP ratingA+
Next earnings2026-08-05
What the experts actually said 0 traceable claims on ALL · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
The Allstate Corporation (NYSE: ALL) is a ~95-year-old US property & casualty insurer headquartered in Northbrook, IL, and one of the largest personal-lines carriers in the country (212 million policies in force). Fiscal year ends December 31. Four reported segments:
Allstate Protection (Property-Liability) — the engine: standard auto and homeowners insurance under the Allstate, National General, Encompass and Custom360 brands, plus specialty vehicle lines. This is ~90% of revenue.
Allstate Health and Benefits — life, accident, and supplemental health (materially shrunk after the 2025 sale of the employer-voluntary-benefits and group-health businesses).
By segment: Property-Liability $59.7B (~90%) · Protection Services $3.55B · Allstate Health & Benefits $0.68B (down from $2.54B in FY24 after divestitures).
By geography (latest available, FY2023 filing): United States ~96% ($54.7B), non-US ~$2.1B, EU ~$0.35B. This is an almost purely domestic US personal-lines franchise — no meaningful international diversification.
The economic story is simple: underwrite auto and home profitably (a low combined ratio), grow policies in force via "Transformative Growth" (affordability, new products, direct + independent-agent distribution), and earn investment income on the float. In Q1'26 the recorded Property-Liability combined ratio was a very strong 82.0 (a ratio below 100 means underwriting profit).
2. The expert thesis — (none in the Synthos KB)
There is no expert coverage of Allstate in the Synthos knowledge base: total_claims = 0, 0 net-bullish voices, 0 traceable claim_ids. We will not manufacture conviction we do not have. Everything below is fundamentals- and quant-driven off the FMP data and Allstate's own SEC filings; no expert-claim citations exist for this name, and none are fabricated.
For external context only (not Synthos conviction): the sell-side is lukewarm — 1 Strong Buy, 20 Buy, 22 Hold, 1 Sell → "Hold" consensus, with an average price target ($250) sitting right at the current price. That neutral posture is consistent with our own read.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
5 · Moderate
Fortress-ish: net-debt/EBITDA 0.4×, beta 0.19, low drawdown, A+ letter rating. But earnings sit at a benign-cat / reserve-release peak, P/B is a rich 2.05×, and RSI 84 at the 52-wk high is a poor entry. Structural cat/reserve cyclicality caps the safety score.
Growth Quality
4 · Below-average
Mid-single-digit premium and PIF growth is real and durable, but consensus EPS declines FY26E→FY28E ($30.2 → $25.5) as underwriting luck normalizes. High ROE (44% TTM) is cyclically inflated.
Exponential Potential
2 · Low
Mature, ~96%-domestic personal-lines insurer in a saturated TAM. No acceleration — the 2nd derivative of earnings is negative. This is a slow compounder / income name, structurally not an exponential.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities. Because ALL is a cyclical, we anchor on normalized (mid-cycle) EPS and a P&C-appropriate multiple, cross-checked against price-to-book.
Case
Key assumptions
Fair value
Bull
Hard market persists, cat losses stay benign, Transformative Growth keeps compounding PIF; earnings hold near the FY26E ~$30 level and the market pays ~10× + credit for the buyback. Book compounds to ~$130.
~$300 (+20%)
Base(our anchor)
Underwriting normalizes toward mid-cycle: EPS settles ~$26–27 (in line with FY27E $26.1). A P&C insurer at mid-cycle earns ~9.5× → ~$250; cross-check ~1.9× a ~$128 book → ~$243. Blend ~$245.
~$245 (−2%)
Bear
A heavy catastrophe year and/or adverse reserve development returns the combined ratio toward the high-90s; EPS drops toward ~$20 and the multiple de-rates to ~9× / book multiple compresses to ~1.6×.
~$190 (−24%)
Synthos fair value = the base case, ~$245 (−2%), with the full $190–$300 span as the honest range. That base sits essentially on top of the Street's $250 consensus — we and the sell-side agree there is little upside from here at a cyclical peak. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). Allstate is neither an exponential nor, right now, an accelerating compounder:
Forward growth: revenue is roughly flat-to-low-single-digit on the estimate strip (FY25 $66.5B → FY28E ~$66.3B avg), and EPS is modeled to decline FY26E $30.20 → FY27E $26.15 → FY28E $25.47. That is normalization, not growth.
Acceleration (the 2nd derivative) is negative. The earnings surge of 2025–26 came from a swing out of the 2022–24 cat/inflation trough (FY23 was a GAAP loss). Off that rebound peak the estimates roll over — the opposite of the accelerating profile an exponential needs.
Room to run: the US personal-auto and homeowners TAM is large but saturated and shared with Progressive, State Farm, GEICO, Travelers and others. At a $64B cap, ALL is not a "small name with a huge runway"; growth is a share- and price-grind, not a category explosion.
Reinvestment runway: capital is returned (dividend + buyback) rather than reinvested at expanding returns — the correct policy for a mature insurer, but the tell of a compounder, not an exponential.
Exponential Potential: Low (2/10). Own Allstate, if at all, for a low-beta dividend and cyclical underwriting upside — never for a multibagger.
Revenue: FY25 $66.46B (+4.6% vs FY24 $63.52B; FY23 $56.59B). Growth is premium-rate- and PIF-driven, mid-single-digit.
The cyclicality, in one line: net income swung from a −$0.19B loss (FY23) and −$1.29B (FY22) — the auto-inflation / catastrophe trough — to $4.67B (FY24) to $10.28B (FY25). This is a classic P&C cycle; do not extrapolate the top.
Quarterly trajectory: the last four quarters (Q2'25 $16.55B → Q3 $17.06B → Q4 $16.59B → Q1'26 $16.94B) show revenue plateauing; the earnings strength is a margin/combined-ratio story, not a volume story.
Underwriting (the real driver): Q1'26 Property-Liability combined ratio 82.0 (vs 97.4 a year ago), helped by catastrophe losses down 43.7% YoY and an $838M prior-year auto reserve release (8.8 pts of benefit). Both tailwinds are, by nature, non-recurring — the underlying (ex-cat, ex-release) combined ratio was ~80–90, still good but less spectacular.
Margins (TTM): net margin ~18%, ROE 44% (cyclically inflated), ROIC ~31%. These are peak-of-cycle figures.
Balance sheet: total debt $7.5B, net debt $6.8B, net-debt/EBITDA ~0.4×, book value per share $113.52 (Q1'26, +52% YoY as AOCI recovered). Investment-grade, A+ letter rating. Low current ratio (0.38) is normal for an insurer (float structure), not a red flag.
6. Valuation — cheap, or cheap for a reason?
The headline is seductive: 5.5× trailing EPS, EV/EBITDA 4.4×, ~18% earnings yield. But that trailing EPS (~$46.8 TTM) embeds a benign-cat, reserve-release windfall. The honest lens for a cyclical is forward/normalized earnings and price-to-book:
Forward P/E: $250 / FY26E $30.20 = 8.3×; / FY27E $26.15 = 9.6×. Cheap but not extraordinary for a P&C insurer, and it rises as EPS normalizes down.
Price-to-book: 2.05× on a $113.52 book — that is toward the rich end of Allstate's own history (P&C insurers frequently trade 1.2–1.7× book; a 2× multiple already prices in strong ROE persistence).
Reverse read: at 2× book with a 44% peak ROE, the market is not pricing distress — it is pricing continued good underwriting. The margin of safety is thin precisely because the good news is in the number.
Street targets (context): consensus $250, high $281, low $225 — a tight band essentially at the current price. Our $245 base is right in it.
Not a value trap, but not the bargain the trailing multiple implies — a fairly-priced cyclical at the top of its earnings cycle.
7. Technicals (from the tech block)
Trend:up. $250.33 sits above the 50-DMA ($219.8) and 200-DMA ($209.3), 50 above 200 (golden-cross posture). MACD +7.5 (positive).
Location:exactly at the 52-week high (0% off; $250.38 high), +32% off the 52-week low ($190). No drawdown cushion at all.
Momentum:RSI(14) 83.9 — clearly overbought (>70). This is a stretched entry; historically a mean-reversion setup rather than a fresh-money add point.
Relative strength: ALL +25% 12-mo vs SPY +20.6% and QQQ +30.3%; +22.7% 3-mo vs SPY +13.7%. Recent leadership, but it has run.
Read: technicals say momentum is strong but the tank is full. An 84 RSI at a fresh high argues for patience — wait for a pullback toward the rising 50-DMA (~$220) rather than chasing.
8. Moat & competitive position
Allstate's advantages are real but ordinary for a scaled insurer: brand ("You're in good hands"), scale in data/underwriting (Arity telematics, sophisticated rating plans), and multi-channel distribution (captive agents, independent agents via Custom360/National General, and direct). "Transformative Growth" — affordability, new products, lower expenses, more marketing — is winning share in auto and homeowners in many states. But personal lines is a commoditized, price-competitive business with no switching-cost moat: customers shop on price, and pricing power is capped by regulators (state rate approvals) and by rivals.
Peer set (market cap): Progressive $135.7B (the growth benchmark and share-taker), Chubb $140.1B, Travelers $72.8B, Aflac $61.5B, The Hartford $37.8B, Cincinnati Financial $29.7B, W.R. Berkley $26.8B. Against Progressive — faster-growing, consistently lower combined ratio, richer multiple — Allstate is the value/turnaround name, not the quality leader. That gap is the crux of the bull-vs-Progressive debate.
9. Management, capital allocation & guidance
Capital allocation: shareholder-friendly and disciplined — a growing dividend ($4.16/yr, ~1.66% yield, ~10% payout) plus buybacks ($1.23B repurchased FY25; shares out down 2.8% YoY to 257.8M). Net-debt/EBITDA ~0.4× leaves ample flexibility. The 2025 divestiture of the employer-voluntary-benefits / group-health businesses sharpened the focus on core P&C.
Insider activity: the sampled Form 4s (through 2026-07-01) are routine equity-comp vesting, RSU conversions and tax-withholding ("F-InKind") transactions by a director and officers — no cluster of alarming open-market discretionary selling in the window. Neutral signal.
Management's own guidance (half-weighted — their own book): Allstate's Q1'26 earnings release (SEC 8-K, filed 2026-04-29) is a real earnings document. CEO Tom Wilson reported Q1'26 revenue of $16.9B, net income $2.4B, adjusted EPS $10.65, policies in force of 212M, and a strong Property-Liability combined ratio of 82.0 with the underlying combined ratio improving across all personal lines. The release emphasizes market-share gains in auto and homeowners, record new business, 9.8% higher investment income, and increased dividends and buybacks. Note: the release is a results document — it does not contain explicit forward numeric EPS/revenue guidance; management frames the outlook qualitatively (continued Transformative Growth, affordability, growth in PIF). Treat these as management's self-interested framing, half-weighted, and lean on the analyst estimate strip (which points to normalization) for the forward path.
10. Catalysts & what to watch
Next earnings: 2026-07-29 (Q2'26; Street EPS $5.16, revenue ~$15.5B). Q2 is a seasonally high-catastrophe quarter (spring/summer storms) — the key test of whether the benign-cat run continues.
Catastrophe losses: hurricane season and wildfire exposure (California remains a live issue) — the single biggest swing factor for earnings.
Prior-year reserve development: watch whether releases continue (a tailwind) or reverse (a headwind); Q1'26's $838M auto release flattered results.
Auto & homeowners combined ratios (underlying): the durable, ex-luck margin — the real health metric.
Rate adequacy & PIF growth: can Allstate keep growing policies and hold margins as it lowers new-business prices for affordability.
Thesis tripwires (what would change the call): a heavy-cat quarter pushing the combined ratio back toward the high-90s; adverse reserve development; PIF growth stalling; or, conversely, a meaningful pullback in price that restores a margin of safety (which would upgrade the entry, not the business).
11. Key risks
Catastrophe cyclicality (structural): earnings are hostage to weather — hurricanes, convective storms, and California wildfires. Today's low combined ratio is partly luck, and luck reverts.
Reserve-release dependence: a chunk of recent profit came from releasing prior-year reserves; this is finite and can reverse into adverse development.
Peak-cycle valuation: buying at 2× book / a 44% peak ROE and a fresh 52-wk high leaves little margin for a normal down-year.
Commoditized, regulated business: no switching-cost moat; pricing gated by state regulators; Progressive and others are aggressive share-takers.
Geographic concentration: ~96% US personal lines — no international diversification to smooth a bad domestic cat year.
Technically extended: RSI 84 at the high raises near-term mean-reversion risk.
12. Verdict, position sizing & monitoring
Watch. Allstate is a well-run, low-beta, cash-generative, A+-rated insurer executing its Transformative Growth plan and returning capital — genuinely a good business. But the case for buying today is weak: the headline cheapness rests on peak-cycle earnings (benign catastrophes + an $838M reserve release), the Street's own estimates have EPS declining ~$30 → ~$25 through 2028, the stock trades at a rich 2× book and a fresh 52-week high on an 84 RSI, and the $250 consensus target implies no upside. There is no expert conviction in the Synthos KB to override that quant read. Right company, wrong entry.
Sizing: if held, a small (~1–2%) defensive/income sleeve, not a conviction position. We would not initiate here; a pullback toward the rising 50-DMA (~$220) or a proof point that the underlying (ex-cat) combined ratio is durably lower would improve the setup.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print, with special attention to Q2'26 cat losses (2026-07-29). This verdict is logged as a tracked Synthos call as of 2026-07-03 at $250.33.
Single biggest risk: catastrophe/reserve normalization — the earnings you are paying for at this price are not the mid-cycle earnings.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — Allstate has no expert coverage in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no claim_ids are cited because none exist. Fabricated conviction is structurally impossible (claim-ID reconciliation), and none was invented here.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-03 · management guidance from the SEC 8-K earnings release filed 2026-04-29. Forward figures are analyst consensus (FMP), labeled as estimates.
Management caveat: Allstate's earnings-release framing is management's own book, half-weighted by design; the release contains results, not explicit numeric forward guidance.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").